Results 11 to 20 of about 118,212 (266)

Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross‐over study

Clinical and Translational Science, 2021
The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive on four separate occasions: (A) orally administered metformin (1 g), (B) intravenously ...
Ida Kuhlmann, Amanda Nøddebo Nyrup, Tore Bjerregaard Stage, Mette Marie Hougaard Christensen, Troels Korshøj Bergmann, Per Damkier, Flemming Nielsen, Kurt Højlund, Kim Brøsen   +8 more
doaj   +1 more source

Biochemical and histopathological evaluation of the effect of metformin and metformin nanoparticles against alloxan-induced diabetes in Rats [PDF]

Benha Veterinary Medical Journal, 2022
Nanoparticles drug delivery systems are nanometric carriers that enhance drugs delivery and therapeutic action. The current study aimed to investigate the effect of daily oral administration of metformin and metformin nanoparticles (45 mg/kg b.
Aya Allah Salem
doaj   +1 more source

Phosphoproteomic analysis of metformin signaling in colorectal cancer cells elucidates mechanism of action and potential therapeutic opportunities

Clinical and Translational Medicine, 2023
Background The biguanide drug metformin is a safe and widely prescribed drug for type 2 diabetes. Interestingly, hundreds of clinical trials have been set to evaluate the potential role of metformin in the prevention and treatment of cancer including ...
Barbora Salovska, Erli Gao, Sophia Müller‐Dott, Wenxue Li, Carlos Chacon Cordon, Shisheng Wang, Aurelien Dugourd, George Rosenberger, Julio Saez‐Rodriguez, Yansheng Liu   +9 more
doaj   +1 more source

Patient-factors associated with metformin steady-state levels in type 2 diabetes mellitus with therapeutic dosage

Journal of Clinical & Translational Endocrinology, 2018
Aims: This prospective study aimed to analyze metformin steady-state concentration in repeated constant dosage and the influencing patient-factors as well as to correlate them with glycemic control.
Vitarani D.A. Ningrum, Zullies Ikawati, Ahmad H. Sadewa, Mohammad R. Ikhsan   +3 more
doaj   +1 more source

COMPARISON OF BLADDER CANCER CELLS APOPTOSIS INDUCED BY METFORMIN, CISPLATIN, AND COMBINATION OF METFORMIN-CISPLATIN: IN VITRO STUDY

Jurnal Urologi Indonesia, 2020
Objective: To evaluate the effect of metformin, cisplatin, and their combination on apoptosis of bladder cancer cells. Material & Methods: Urothelial cell lines 5637 were cultured until 80% confluence.
Arifai Lumbangaol, Lukman Hakim, Doddy M Soebadi, Tarmono Djojodimedjo   +3 more
doaj   +1 more source

Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner

OncoImmunology, 2021
Metformin, a drug prescribed to treat type 2 diabetes, has been reported to possess antitumor activity via immunity activation. However, the influence of metformin on natural killer (NK) cells is not fully understood.
Wenjiao Xia, Xin Qi, Mingfeng Li, Yu Wu, Lulu Sun, Xinglong Fan, Yuan Yuan, Jing Li   +7 more
doaj   +1 more source

Analysis of Time Course and Dose Effect From Metformin on Body Mass Index in Children and Adolescents

Frontiers in Pharmacology, 2021
The purpose of this study was to analyze the time course and dose effect from metformin on body mass index (BMI) in children and adolescents by model-based meta-analysis (MBMA).
Dong-Dong Wang, Yi-Zhen Mao, Su-Mei He, Xiao Chen, Xiao Chen, Xiao Chen   +5 more
doaj   +1 more source

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes.

PLoS ONE, 2018
ObjectiveMetformin use is restricted in patients with renal impairment due to potential excess systemic accumulation. This study evaluated the glycemic effects and safety of metformin delayed-release (Metformin DR), which targets metformin delivery to ...
Robert R Henry, Juan P Frias, Brandon Walsh, Sharon Skare, John Hemming, Colleen Burns, Thomas A Bicsak, Alain Baron, Mark Fineman   +8 more
doaj   +1 more source

Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth. [PDF]

PLoS ONE, 2015
Recently, the pleiotropic benefits of incretin-based therapy have been reported. We have previously reported that Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist, attenuates prostate cancer growth.
Yoko Tsutsumi, Takashi Nomiyama, Takako Kawanami, Yuriko Hamaguchi, Yuichi Terawaki, Tomoko Tanaka, Kunitaka Murase, Ryoko Motonaga, Makito Tanabe, Toshihiko Yanase   +9 more
doaj   +1 more source

Metformin in pregnancy

Polish Gynaecology, 2014
Metformin is an oral insulin-sensitizing anti-diabetic drug. Polycystic ovary syndrome (PCOS) and gestational diabetes (GDM) are both associated with insulin resistance and hyperinsulinemia. Metformin can bring potential benefits in pregnant women due to its favorable metabolic effect.
Julia, Bijok, Małgorzata, Bińkowska, Grzegorz, Jakiel   +2 more
openaire   +2 more sources